<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01796392</url>
  </required_header>
  <id_info>
    <org_study_id>600-0012</org_study_id>
    <nct_id>NCT01796392</nct_id>
  </id_info>
  <brief_title>Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)</brief_title>
  <acronym>LIBERATE</acronym>
  <official_title>Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmonx, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study a medical device that is designed to produce lung
      volume reduction.  This device is called the PulmonX Endobronchial Valve (EBV). It has not
      been approved by the Food and Drug Administration (FDA) and is considered investigational.
      The EBV is a one-way valve that blocks off the diseased lung section to inhaled air but lets
      the trapped air already inside the area escape.  With placement of the EBV, the diseased
      part of the lung collapses which allows the healthier parts of the lung to expand.

      The EBV can be placed by a doctor in a diseased section of the lungs using bronchoscopy.
      Bronchoscopy is a way to access the lungs using a small tube with a camera on the end.  With
      bronchoscopy, a physician can reach the airways in the lung by passing the tube through
      either the mouth or nose.  Use of bronchoscopy for performing lung volume reduction may have
      fewer risks than surgery and have reduced recovery time.

      This study is designed to investigate the safety and effectiveness of the Pulmonx EBV for
      treating emphysema symptoms as compared to a standard medical therapy program alone.  It is
      hypothesized that after placement of the EBV, lung function will be improved as compared to
      standard medical therapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Forced expiratory volume in 1-second (FEV1)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric reduction of the treated area of the lung</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>EBV and Optimal Medical Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Management</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EBV</intervention_name>
    <description>This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.</description>
    <arm_group_label>EBV and Optimal Medical Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Management</intervention_name>
    <description>This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.</description>
    <arm_group_label>Optimal Medical Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and radiological evidence of emphysema

          -  Currently non-smoking

          -  Stable on current medication regimen

          -  Forced expiratory volume in one second (FEV1) between 15% and 45% of predicted value

        Exclusion Criteria:

          -  Had two or more hospitalizations over the last year for a COPD exacerbation

          -  Had two or more hospitalizations over the last year for pneumonia

          -  Had a prior lung transplant, lung volume reduction surgery, bullectomy or lobectomy

          -  Had a heart attack or congestive heart failure within the last 6 months

          -  Have heart arrhythmia

          -  Is alpha-1 antitrypsin deficient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Hospital, Philadelphia, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armin Ernst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reliant Medical Group, Worcester, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Smith, RN, BSN</last_name>
      <phone>205-996-5392</phone>
      <email>psmith@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Necole Harris</last_name>
      <phone>205-934-9240</phone>
      <email>kanicky@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Dransfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Thomas</last_name>
      <phone>602-240-3383</phone>
      <email>tthomas@azoncology.com</email>
    </contact>
    <investigator>
      <last_name>Richard Sue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Weldon, MA</last_name>
      <phone>323-442-5763</phone>
      <email>Amelia.Weldon@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>M. Paul McFadden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Tham</last_name>
      <phone>916-734-3351</phone>
      <email>tina.tham@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Powers, RN</last_name>
      <phone>619-543-2291</phone>
      <email>atpowers@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Samir Makani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Dincheva</last_name>
      <phone>415-353-7995</phone>
      <email>Gabriela.Dincheva@ucsfmedctr.org</email>
    </contact>
    <contact_backup>
      <last_name>Archer Eller, MS</last_name>
      <phone>415-502-2025</phone>
      <email>Archer.Eller@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Hays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafi Kiledjian, MD</last_name>
      <phone>310-222-8200</phone>
      <email>rkiledjian@labiomed.org</email>
    </contact>
    <investigator>
      <last_name>David Hsia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Boley</last_name>
      <phone>217-545-5000</phone>
      <email>tboley@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Hazelrigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crissie Despirito, RN</last_name>
      <phone>502-852-0026</phone>
      <email>crissie.despirito@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya Wiese, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Dea</last_name>
      <phone>617-789-2078</phone>
      <email>arthur.dea@steward.org</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Herrick</last_name>
      <email>katherine.herrick@steward.org</email>
    </contact_backup>
    <investigator>
      <last_name>Samaan Rafeq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel-Rolando Almario, RN, BSN</last_name>
      <phone>313-916-2433</phone>
      <email>RAlmari1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Lana Saugrich, RN</last_name>
      <phone>313-916-2433</phone>
      <email>LSAUGRI9@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Simoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Smathers</last_name>
      <phone>919-668-3812</phone>
      <email>Emily.Smathers@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Momen Wahidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melody Santiago, RN, BSN</last_name>
      <phone>215-707-9847</phone>
      <email>Melody.Santiago@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Criner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Thoracic Surgery</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Brennan</last_name>
      <phone>206-386-2450</phone>
      <email>christina.brennan@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Sean McHugh</last_name>
      <email>sean.mchugh@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jed Gorden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emphysema</keyword>
  <keyword>endobronchial valve</keyword>
  <keyword>treatments</keyword>
  <keyword>pulmonary rehabilitation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
